Abstract
Macrophages activated to the tumoricidal state can recognize and destroy neoplastic cells and leave normal cells unharmed. Systemic activation of macrophages can be achieved by the intravenous administration of liposomes containing various immunomodulators. Much like any particle, liposomes are cleared from the circulation by phagocytic cells. This passive but specific targeting of immunomodulators to macrophages results in their activation forin vitro andin vivo lysis of tumor cells that can be resistant to conventional therapies.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- MAF:
-
macrophage-activating factor
- MDP:
-
N-acetylmuramyl-L-alanyl-D-isoglutamine
- MLV:
-
multilamellar vesicle
- MTP-PE:
-
N-acetyl-muramyl-L-alanyl-D-isoglutamyl-L-alanyl-2-(1′,2′-dipalmitoyl)-sn-glycero-3′phosphorylethylamide
- PC:
-
phosphatidylcholine
- PS:
-
phosphatidylserine
- RES:
-
reticuloendothelial system
- IFN-γ:
-
interferon-γ
- AM:
-
alveolar macrophage
References
Fidler IJ, Balch CM. The biology of cancer metastasis and implications for therapy. Curr Probl Surg 1987; 24: 137–209.
Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature 1979; 283: 139–46.
Fidler IJ, Poste G. The cellular heterogeneity of malignant neoplasms: Implications for adjuvant chemotherapy. Semin Oncol 1985; 12:207–21.
Nicolson GL. Generation of phenotypic diversity and progression in metastatic tumors. Cancer Met Rev 1984; 3: 25–42.
Fidler IJ, Poste G. Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease. Springer Semin Immunopathol 1982; 5: 161–74.
Fidler IJ. Macrophages and metastasis—A biological approach to cancer therapy: Presidential address. Cancer Res. 1985; 45: 4714–26.
Fidler IJ. Immunomodulation of macrophages for cancer and antiviral therapy. In: Tomlinson E, Davis SS, eds. Site-specific drug delivery. New York: John Wiley and Sons, 1986: 111–35.
Gregoriadis G, ed. Liposomes as drug carriers: Recent trends and progress. New York: John Wiley and Sons, 1988.
Knight CG, ed. Liposomes: From physical structure to therapeutic applications. Amsterdam: Elsevier, 1981.
Gregoriadis G, Neerungun DE, Hunt R. Fate of liposome-associated agents injected into normal and tumor-bearing rodents: Attempts to improve localization in tumor lines. Life Sci 1977; 21: 357–70.
Alving CR. Delivery of liposome-encapsulated drugs to macrophages. Pharmacol Ther 1983; 22: 407–24.
Poste G. Liposome targetingin vivo: Problems and opportunities. Biol Cell 1983; 47: 19–39.
Hwang KJ. Liposome pharmacokinetics. In: Ostro MJ, ed. Liposomes from biophysics to therapeutics. New York: Marcel Dekker, 1987: 109–56.
Schroit AJ, Hart IR, Madsen J, Fidler IJ. Selective delivery of drugs encapsulated in liposomes: Natural targeting to macrophages involved in various disease states. J Biol Response Mod 1983; 2: 97–100.
Koff WC, Fidler IJ. The potential use of liposome-mediated antiviral therapy. Antiviral Res 1985; 228: 495–7.
Fidler IJ. Recognition and destruction of target cells by tumoricidal macrophages. Isr J Med Sci 1978; 14: 177–91.
Fidler U, Kleinerman ES. Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions. J Clin Oncol 1984; 2: 937–43.
Chedid L, Audibert F, Johnson AG. Biological activities of muramyl dipeptide, a synthetic glycopeptide analogous to bacterial immunoregulating agents. Prog Allergy 1978; 25: 63–80.
Lederer E. Synthetic immunostimulants derived from the bacterial cell wall. J Med Chem 1980; 23: 819–25.
Fogler WE, Fidler U. Modulation of the immune response by muramyl dipeptide. In: Chirigos MA, Fenichel RL, eds. Immune modulation agents and their mechanisms. New York: Marcel Dekker, 1984: 499–512.
Allison AC. On the role of mononuclear phagocytes in immunity against viruses. Prog Med Virol 1974; 18: 15–31.
Allison AC. Mode of action of immunological adjuvants. J Reticuloendothel Soc 1979; 26: 619–30.
Gisler RH, Dietrich FM, Baschang G, Brownbill A, Schumann G, Staber FB, Tarcsay L, Wachsmuth ED, Dukor P. New developments in drugs enhancing the immune response: Activation of lymphocytes and accessory cells by muramyl peptides. In: Turk JL, Danker D, eds. Immune responsiveness. London: MacMillan, 1979: 133–60.
Parant M, Parant F, Chedid L, Yapo A, Petit JF, Lederer E. Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse. Int J Immunopharmacol 1979; 1: 35–41.
Fogler WE, Wade R, Brundish DE, Fidler IJ. Distribution and fate of free and liposome-encapsulated [3H]muramyl tripeptide phosphatidylethanolamine in mice. J Immunol 1985; 135: 1372–7.
Fidler IJ, Barnes Z, Fogler WE, Kirsh R, Bugelski P, Poste G. Involvement of macrophages in the eradication of established metastases following intravenous injection of liposome containing macrophage activators. Cancer Res 1982; 42: 496–501.
Fidler IJ, Fogler WE, Tarcsay L, Schumann G, Braun DG, Schroit AJ. Systemic activation of macrophages and treatment of cancer metastases by liposomes containing hydrophilic or lipophilic muramyl dipeptide. Immunopharmacol 1983; 2: 253–352.
Fidler IJ. The MAF dilemma. Lymphokine Res 1984; 3: 51–4.
Kleinerman ES, Fidler IJ. Production and utilization of human lymphokines containing macrophage-activating factor (MAF) activity. Lymphokine Res 1983; 2: 7–12.
Kleinerman ES, Schroit AJ, Fogler WE, Fidler IJ. Tumoricidal activity of human monocytes activatedin vitro by free and liposome-encapsulated human lymphokines. J Clin Invest 1983; 72: 1–12.
Saiki I, Fidler IJ. Synergistic activation by recombinant mouse interferon-gamma and muramyl dipeptide of tumoricidal properties in mouse macrophages. J Immunol 1985; 135: 684–8.
Saiki I, Sone S, Fogler WE, Kleinerman ES, Lopez-Berestein G, Fidler IJ. Synergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes. Cance Res 1985; 45: 6188–93.
Fidler IJ, Fogler WE, Kleinerman ES, Saiki I. Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human gamma interferon encapsulated in liposomes. J Immunol 1985; 135: 4289–94.
Hibbs JB Jr. Discrimination between neoplastic and non-neoplastic cells byin vitro activated macrophages. J Natl Cancer Inst 1974; 53: 1487–92.
Hibbs JB Jr. Heterocytolysis by macrophages activated by bacillus Calmette-Guerin: Lysosome exocytosis into tumor cells. Science 1974; 184: 468–71.
Bucana CD, Hoyer LL, Hobbs B, Breesman S, McDaniel M, Hanna MG Jr. Morphological evidence for the translocation of lysosomal organelles from cytotoxic macrophages into the cytoplasm of tumor target cells. Cancer Res. 1976; 36: 4444–58.
Bucana CD, Hoyer LC, Schroit AJ, Kleinerman ES, Fidler IJ. Ultrastructural studies of the interaction between liposome-activated human blood monocytes and allogeneic tumor cellsin vitro. Am J Pathol 1983; 112: 101–11.
Fogler WE, Fidler IJ. Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages. Cancer Res 1985; 45: 14–8.
Fidler IJ, Raz A, Fogler WE, Kirsh R, Bugelski P, Poste G. The design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages. Cancer Res 1980; 40: 4460–6.
Poste G, Kirsh R, Bugelski P. Liposomes as a drug delivery system in cancer therapy. In: Sunkara P, ed. Novel approaches to cancer chemotherapy. New York: Academic Press, 1984: 323–35.
Fidler IJ. Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines. Science 1980; 208: 1469–71.
Fidler IJ, Sone S, Fogler WE, Smith D, Braun DG, Tarcsay L, Gisler RJ, Schroit AJ. Efficacy of liposomes containing a lipophilic muramyl dipeptide for activating the tumoricidal properties of alveolar macrophagesin vivo. J Biol Response Mod 1982; 1: 43–55.
Mehta K, Lopez-Berestein G, Hersh EM, Juliano RL. Uptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes. J Reticuloendothel Soc 1982; 32: 155–64.
Nayar R, Schroit AJ. Generation of pH-sensitive liposomes: Use of large unilamellar vesicles containing N-succinylphosphatidylethanolamine. Biochemistry 1985; 24: 5967–71.
Poste G, Bucana CD, Raz A, Bugeslki P, Kirsh R, Fidler IJ. Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res 1982; 42: 1412–22.
Kleinerman ES, Fogler WE, Fidler IJ. Intracellular activity of human and rodent macrophages by human lymphokines encapsulated in liposomes. J Leukocyte Biol 1985; 37: 571–84.
Fidler IJ, Raz A, Fogler WE, Hoyer LC, Poste G. Role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes. Cancer Res 1981; 41: 495–504.
Raz A, Bucana C, Fogler WE, Poste G, Fidler IJ. Biochemical morphological and ultrastructural studies on the uptake of liposomes by murine macrophages. Cancer Res 1981; 41: 487–94.
Schroit AJ, Fidler IJ. Effects of liposome structure and liquid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res 1982; 42: 161–7.
Schroit AJ, Galligioni E, Fidler IJ. Factors influencing thein situ activation of macrophages by liposomes containing muramyl dipeptide. Biol Cell 1983; 47: 87–94.
Xu ZL, Fidler IJ. Thein situ activation of cytotoxic properties in mutine Kupffer cells by the systemic administration of whole Mycobacterium bovis organisms or muramyl tripeptide. Cancer Immunol Immunother 1984; 18: 118–22.
Daemen T, Veniga A, Roerdink FH, Scherphof GL.In vitro activation of rate liver macrophages to tumoricidal activity by free or liposome-encapsulated muramyl dipeptide. Cancer Res 1986; 46: 4330–5.
Daemen T, Veninga A, Scherphof GL, Roerdink FH. The activation of Kupffer cells to tumor cytotoxicity with immunomodulators encapsulated in liposomes. In: Kirn A, Knock DL, Wisse E, eds. Cell of the hepatic sinusoid. Rijswijk, The Netherlands: The Kupffer Cell Foundation, 1986: 379–83.
Sone S, Fidler IJ. Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages. J Immunol 1980; 125: 2454–60.
Sone S, Fidler IJ.In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes. Cell Immunol 1981; 57: 42–50.
Fidler IJ, Jessup JM, Fogler WE, Staerkel R, Mazumder A. Activation of tumoricidal properties in peripheral blood monocytes of patients with colorectal carcinoma. Cancer Res 1986; 44: 994–8.
Lopez-Berestein G, Mehta K, Mehta R, Juliano RL, Hersh EM. The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues. J Immunol 1983; 130: 1500–4.
Sone S, Utsugi T, Tandon P, Ogawara M. A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the anticancer state. Cancer Immunol Immunother 1986; 22: 191–6.
Sone S, Mutsuura S, Ogawara M, Tsubura E. Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes. J Immunol 1984; 132: 2105–10.
Sone S, Tsubura E. Human alveolar macrophages: Potentiation of their tumoricidal activity by liposome-encapsulated muramyl dipeptide. J Immunol 1982; 129: 1313–7.
Kleinerman ES, Erickson KL, Schroit AJ, Fogler WE, Fidler IJ. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res 1983; 43: 2010–4.
Fidler IJ, Schroit AJ. Macrophage recognition of self from nonself: Implications for the interaction of macrophages with neoplastic cells. In: Kripke ML, Frost P, eds. Immunology and cancer. Austin: University of Texas Press, 1986: 183–207.
Szoka F, Papahadjopoulos D. Prodedure for preparation of liposomes with large internal aqueous space and high capture by reverse phase evaporation. Proc Natl Acad Sci USA 1978; 75: 4914–8.
Fidler IJ, Schroit AJ. Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes:In situ activation of macrophages and therapy of spontaneous cancer metastasis. J Immunol 1984; 133: 515–8.
Deodhar SR, James K, Chiang T, Edinger M, Bama B. Inhibition of lung metastases in mice bearing a malignant fibrosarcoma by treatment with liposomes containing human c-reactive protein. Cancer Res 1982; 42: 5084–91.
Key ME, Talmadge JE, Fogler WE, Bucana C, Fidler IJ. Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide. J Natl Cancer Inst 1982; 69: 1189–98.
LeGrue SJ, Romerdahl CA, Saiki I, Fidler IJ. Systemic macrophage activation by liposomes containing MTP-PE in mice immunosuppressed with cyclosporine-A. Transplantation 1987; 43(4): 584–6.
Fidler IJ, Sone S, Fogler WE, Barnes ZL. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA 1981; 78: 1680–4.
Sadler TE, Jones DDE, Castro JE. The effects of altered phagocytic activity on growth of primary and metastatic tumors. In: McBride JF, Stuart A, eds. The macrophage and cancer. Edinburgh: Econoprint, 1979: 115–63.
Mantovani A, Giavazzi R, Polentanitti N, Spreafico F, Garattini S. Divergent effects of macrophage toxins on growth of primary tumors and lung metastases in mice. Int J Cancer 1980; 25: 617–24.
Fidler IJ, Fan D, Ichinose Y. Potentin situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidy lethanolamine and interferon gamma. Inv Metastasis 1989; 9: 75–88.
Eppstein DA, Van der Pas MA, Fraser-Smith EB, Kurahara CG, Feigner PL, Mathews TR, Waters RV, Venuti MC, Jones GH, Metha R, Lopez-Berestein G. Liposome encapsulated muramyl dipeptide analogue enhances non-specific host immunity. Int J Immunotherapy 1986; 2: 115–26.
Deodhar SD, Bama BP, Edinger M, Chiant T. Inhibition of lung metastases by liposomal immunotherapy in a murine fibrosarcoma model. J Biol Response Mode 1982; 1: 27–34.
Lopez-Berestein G, Milas L, Hunter N, Mehta K, Eppstein D, Van der Pas MA, Mathews TR, Hersh EM. Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome-encapsulated 6-0-steroyl-N-acetyl muramyl-l-amino-butyryl-d-isogulutamine. Clin Exp Metastasis 1984; 2(2): 366–7.
Phillips NC, Mora ML, Chedid L, Lefrancier P, Bernard JM. Activation of tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative. Cancer Res 1985; 45: 128–34.
Thombre P, Deodhar SD. Inhibition of liver metastases in murine colon adenocarcinoma by liposomes containing human c-reactive protein or crude lymphokine. Cancer Immunol Immunother 1984; 16: 145–50.
Talmadge JE, Lenz BF, Klabansky R, Simon R, Riggs C, Guo S, Oldham RK, Fidler IJ. Therapy of autochthonous skin cancers in mice with intravenously injected liposomes containing muramyltripeptide. Cancer Res 1986; 46: 1160–3.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pak, C.C., Fidler, I.J. Liposomal delivery of biological response modifiers to macrophages. Biotherapy 3, 55–64 (1991). https://doi.org/10.1007/BF02175099
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02175099